Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
IMKELDI vs COLUMVI
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Imkelde (imipenem/cilastatin/relebactam) is a combination antibacterial agent. Imipenem inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs). Cilastatin inhibits renal dehydropeptidase I, preventing renal metabolism of imipenem. Relebactam is a beta-lactamase inhibitor that protects imipenem from degradation by certain serine beta-lactamases, including KPC and some Amp C enzymes.
CD20-directed cytolytic antibody; binds to CD20 antigen on B-lymphocytes, inducing antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis.
FDA-approved: Treatment of complicated urinary tract infections including pyelonephritis in adults,FDA-approved: Treatment of complicated intra-abdominal infections in adults,FDA-approved: Treatment of hospital-acquired and ventilator-associated bacterial pneumonia in adults,Off-label: Treatment of bacteremia due to susceptible gram-negative pathogens,Off-label: Treatment of infections due to carbapenem-resistant Enterobacteriaceae (CRE)
Relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy,Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy
10 mg orally once daily
12 mg/kg intravenously on Day 1 of each 21-day cycle for 12 cycles in combination with bendamustine. For patients with relapsed or refractory follicular lymphoma after two or more prior therapies, the recommended dose is 12 mg/kg intravenously on Day 1 of each 28-day cycle until disease progression or unacceptable toxicity.
Terminal elimination half-life: 12 hours (range 10-14 hours) in healthy adults; extended to 24-30 hours in moderate renal impairment (Cr Cl 30-50 m L/min). Clinical context: Steady state achieved after 3-4 days. Twice-daily dosing maintains therapeutic levels.
Terminal half-life approximately 20 days (range 14-28 days), consistent with Ig G1 monoclonal antibody clearance via intracellular catabolism.
Imipenem is metabolized in the kidney by dehydropeptidase I. Cilastatin is a competitive inhibitor of this enzyme and is also partially metabolized renally. Relebactam is minimally metabolized, primarily eliminated unchanged in urine. The combination has a half-life of approximately 1 hour. No significant hepatic metabolism.
Metabolized via non-specific proteolysis into small peptides and amino acids; not metabolized by CYP450 enzymes.
Primarily renal excretion of unchanged drug and metabolites; 70% recovered in urine (60% unchanged, 10% as glucuronide conjugate) and 30% in feces (mainly metabolites) over 72 hours.
Primarily eliminated via biliary/fecal route; renal excretion is minimal (less than 1% of dose).
98% bound to serum albumin.
No specific protein binding data; as a monoclonal antibody, it is not bound to plasma proteins in a significant manner.
0.2 L/kg (approx. 14 L in 70 kg adult). Low Vd indicates distribution primarily in extracellular fluid and plasma, consistent with high protein binding and limited tissue penetration.
Approximately 4.5 L (0.06 L/kg assuming 70 kg), indicating limited extravascular distribution, primarily confined to plasma and interstitial space.
Oral: 85% (high bioavailability, minimal first-pass metabolism).
Intravenous administration yields 100% bioavailability.
No dose adjustment required for mild to moderate renal impairment (GFR ≥30 m L/min). Not recommended for severe renal impairment (GFR <30 m L/min).
No dose adjustment recommended for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not studied in severe renal impairment (Cr Cl <30 m L/min) or on dialysis.
Child-Pugh A: No dose adjustment. Child-Pugh B: 5 mg orally once daily. Child-Pugh C: Not recommended.
No dose adjustment recommended for mild hepatic impairment (Child-Pugh A). Not studied in moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment.
Safety and efficacy not established in pediatric patients.
Safety and effectiveness in pediatric patients have not been established.
No specific dose adjustment recommended; consider starting at the lower end of the dosing range due to potential age-related renal impairment.
No specific dose adjustment recommended for elderly patients (≥65 years). Clinical studies included patients up to 88 years; no overall differences in safety or efficacy observed.
None. There is no FDA boxed warning for Imkelde.
WARNING: CYTOKINE RELEASE SYNDROME (CRS). Serious or life-threatening CRS can occur, including infusion-related reactions. Premedicate and monitor during infusion. Withhold or permanently discontinue as recommended.
Hypersensitivity reactions: Serious and occasionally fatal hypersensitivity reactions (including anaphylaxis) may occur. Cross-allergenicity with other beta-lactams.,Seizures: Higher risk in patients with CNS disorders or renal impairment. Dose adjustment for renal function is required.,Clostridioides difficile-associated diarrhea (CDAD): Can range from mild diarrhea to fatal colitis.,Renal impairment: Dose adjustment necessary; monitor renal function.,Development of drug-resistant bacteria: Overuse may promote resistance.,Interference with laboratory tests: May cause positive direct Coombs test.
Cytokine release syndrome (CRS), including serious or life-threatening reactions,Neurologic toxicity, including immune effector cell-associated neurotoxicity syndrome (ICANS),Infections, including serious and opportunistic infections,Tumor flare reaction,Embryo-fetal toxicity
Known hypersensitivity to any component of Imkelde (imipenem, cilastatin, relebactam) or other beta-lactam antibiotics.,Contraindicated in patients with severe hypersensitivity (e.g., anaphylaxis) to any beta-lactam.
None known.
Grapefruit and grapefruit juice increase drug exposure and should be avoided. High-fat meals may slightly increase absorption, but consistent timing with meals is recommended.
Avoid grapefruit and grapefruit juice. No other specific food interactions reported. Maintain adequate hydration to prevent tumor lysis syndrome.
First trimester: No adequate human data; animal studies show fetal anomalies at maternal toxic doses. Second and third trimesters: Risk of fetal hypoglycemia and hyperinsulinemia due to KATP channel blockade; avoid unless maternal benefit outweighs risk.
COLUMVI (glofitamab) is a CD3/CD20 bispecific antibody. Based on its mechanism of action and animal studies, there is a potential for fetal harm. Ig G molecules cross the placenta; fetal exposure increases as pregnancy progresses, with the largest amount transferred during the third trimester. Glofitamab may cause fetal B-cell depletion and immune dysfunction. There are no adequate human data. Contraindicated during pregnancy; advise effective contraception during treatment and for 3 months after the last dose.
Excreted in breast milk; M/P ratio unknown. Potential for infant hypoglycemia; use with caution and monitor infant blood glucose.
No data on presence in human milk, effects on the breastfed child, or milk production. Human Ig G is secreted into breast milk, but minimal systemic absorption in the infant is expected. Because of potential for serious adverse reactions (including B-cell depletion), advise patients not to breastfeed during treatment and for at least 3 months after the last dose. M/P ratio: unknown.
No specific dose adjustments required; pharmacokinetics unchanged in pregnancy based on limited data. Dose adjustment may be needed for renal function changes.
No clinical trials have evaluated dosing in pregnancy. Pharmacokinetics of therapeutic antibodies are not significantly altered by pregnancy-mediated changes; however, increased plasma volume and altered clearance may occur. No specific dose adjustments are recommended; if benefit outweighs risk, administer at standard dosing (2.5 mg and 10 mg step-up doses, then 30 mg fixed dose every 21 days for up to 12 cycles). Clinical judgment required due to lack of data; consider therapeutic drug monitoring if available.
Monitor renal function closely; dose adjustment required for Cr Cl <30 m L/min. Avoid concurrent use with strong CYP3A4 inhibitors unless benefit outweighs risk. Administer with food to reduce GI upset.
COLUMVI (glofitamab) is a CD3x CD20 bispecific antibody for relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Administer with prior rituximab and premedication to mitigate cytokine release syndrome (CRS). Monitor for CRS closely during step-up dosing; consider tocilizumab for management. Ensure adequate IV hydration and uric acid monitoring for tumor lysis syndrome. Do not coadminister with other systemic immunosuppressants unless necessary. Assess for hepatitis B reactivation prior to initiation.
Take with meals to decrease stomach upset.,Avoid grapefruit juice during treatment.,Report any signs of allergic reaction, such as rash or difficulty breathing, immediately.,Do not drive or operate machinery if you experience dizziness or drowsiness.,Stay hydrated and inform your doctor of any changes in urine output.
COLUMVI is an infusion that helps your immune system attack lymphoma cells.,You will receive a low first dose and gradually higher doses to reduce side effects like fever and chills.,Common side effects include infusion reactions, tiredness, and low blood counts. Report fever, chills, or trouble breathing immediately.,Avoid grapefruit or grapefruit juice during treatment as they may affect how the medication works.,Stay well hydrated and contact your doctor if you have signs of infection or bleeding.,Do not receive live vaccines during treatment and for at least 6 months after the last dose.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about IMKELDI vs COLUMVI, answered by our medical review team.
IMKELDI is a Antineoplastic Agent that works by Imkelde (imipenem/cilastatin/relebactam) is a combination antibacterial agent. Imipenem inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs). Cilastatin inhibits renal dehydropeptidase I, preventing renal metabolism of imipenem. Relebactam is a beta-lactamase inhibitor that protects imipenem from degradation by certain serine beta-lactamases, including KPC and some Amp C enzymes.. COLUMVI is a Antineoplastic Agent (Monoclonal Antibody) that works by CD20-directed cytolytic antibody; binds to CD20 antigen on B-lymphocytes, inducing antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between IMKELDI and COLUMVI depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of IMKELDI is: 10 mg orally once daily. The standard adult dose of COLUMVI is: 12 mg/kg intravenously on Day 1 of each 21-day cycle for 12 cycles in combination with bendamustine. For patients with relapsed or refractory follicular lymphoma after two or more prior therapies, the recommended dose is 12 mg/kg intravenously on Day 1 of each 28-day cycle until disease progression or unacceptable toxicity.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between IMKELDI and COLUMVI in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. IMKELDI is classified as Category C. First trimester: No adequate human data; animal studies show fetal anomalies at maternal toxic doses. Second and third trimesters: Risk of fetal hypoglycemia and hyperinsulinemia d. COLUMVI is classified as Category C. COLUMVI (glofitamab) is a CD3/CD20 bispecific antibody. Based on its mechanism of action and animal studies, there is a potential for fetal harm. IgG molecules cross the placenta; . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.